[Treatment of systemic sclerosis]

Area of Science:

• Immunology
• Rheumatology
• Pulmonology

Context:

• Systemic sclerosis (SSc), or scleroderma, is a severe multisystem autoimmune disease with limited curative treatment options.
• Immune dysregulation is a key factor in SSc pathogenesis, leading to widespread use of immunosuppressive therapies.
• SSc frequently involves critical organ systems, including the lungs, leading to significant morbidity and mortality.

Purpose:

• To review current therapeutic strategies for systemic sclerosis.
• To evaluate the efficacy of immunosuppressive agents and targeted therapies in managing SSc complications.
• To highlight recent advancements in SSc treatment based on clinical trial data.

Summary:

• Cyclophosphamide demonstrated a modest but significant improvement in pulmonary function tests for SSc patients with alveolitis in placebo-controlled trials.
• Prostacyclin analogues and endothelin-1 receptor antagonists have shown efficacy in stabilizing pulmonary arterial hypertension, a life-threatening SSc complication.
• Current treatments aim to manage disease progression and symptoms rather than provide a cure for systemic sclerosis.

Impact:

• Provides an overview of effective treatments for SSc, including cyclophosphamide for lung involvement and specific agents for pulmonary hypertension.
• Informs clinicians about the current evidence supporting immunosuppressive and targeted therapies in managing severe SSc complications.
• Highlights the need for continued research into novel curative strategies for systemic sclerosis, given its poor prognosis.